- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01342328
Providing "Good Sleep" for ICU Sedation (ASRV)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this proposal the investigators seek to determine whether sedation mediated by activation of α2 adrenoceptors (dexmedetomidine) is more like natural sleep than that provided by a sedative agent that modulates the GABAA receptor (propofol), two common widely used sedative agents in ICU. Ten volunteers will be enrolled and each subject will be studied on three experimental sessions. Subjects will be randomized to receive a continuous infusion of either saline, dexmedetomidine (DEX), or propofol in each of the three sessions. By relying on clinical rating scales, the investigators ensure that the doses of DEX and propofol administered induce equisedative states before progressing to magnetoencephalography and electroencephalography data collection.
If the restorative and reparative benefits of sleep mitigate the development of cognitive dysfunction, this will result in shorter ICU length of stay for critically ill patients with a concomitant reduction in healthcare costs. Furthermore, it is possible that the restorative properties of sleep for the central nervous system can extend to the immune system with less infection and/or greater likelihood of survival from sepsis.
In this manner, our project will translate experimental data towards clinical practice and the adoption of rational and clinically supported interventions in the ICU that are likely to improve not only patient reported outcome measures, but also the chance of surviving critical illness.
Each experimental session will take a maximum of 7 hours (5 hours maximum for control sessions).
Sessions have to be separated by at least one week. Subjects will be enrolled for a minimum of 3 weeks (1 session on each week) and no more than 3 months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Volunteer agreement and written informed consent
- Healthy female or male between 18 and 45 years of age
- Body Mass Index < 30 kg/m2
- Non-pregnant and non-lactating
- Normal airway anatomy (Mallampati class I)
Exclusion Criteria:
- Subject has a history of recent alcohol or drug abuse
- Subject is unable to communicate in English
- Subject is unwilling to meet fast guidelines (fast light meal or non-human milk for at least 8 hours, and clear liquids at least for 2 hours prior to induction of sedation on the day of the study)
- Subject has taken caffeine containing beverages less than 8 hours before study begins
- Subject is not able to avoid sleep for a minimum of 16 hours prior to testing
- Subject has a known allergy to either of the sedative-hypnotic drugs to be used in the study
- Subject has abnormal airway anatomy, including loose teeth
- Subject has any family history of complications from anesthesia
- Subject has history of sleep apnea
- Subject has any reported illness, upper respiratory tract infection, abnormal vital signs, or concerning findings on the physical exam for the past 6 weeks
- Subject has a positive urine pregnancy test
- Subject is unable to sleep supine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Control
For this arm, the volunteer subject will receive a saline infusion during the sleep session.
|
Normal saline infusion
|
EXPERIMENTAL: Dexmedetomidine (DEX)
For this arm, the volunteer subject will receive a DEX infusion for sedation during the sleep session.
|
Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions. We aim to achieve an RASS of -3 so that the subjects are "moderately sedated". This state of sedation will be maintained for 3-4 hours.
Other Names:
|
EXPERIMENTAL: Propofol
For this arm, the volunteer subject will receive a propofol infusion for sedation during the sleep session.
|
For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved. Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered. Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compare the electroencephalography features of sleep produced by three sleep-induced regimens
Time Frame: Data will be collected during patient's sleep, which will last 4hours.
|
The investigators will evaluate the "power" in the delta rhythm range and amount of slow-wave-sleep
|
Data will be collected during patient's sleep, which will last 4hours.
|
Compare the magnetoencephalography features of sleep produced by three sleep induced regimens
Time Frame: Data will be collected during patient's sleep, which will last 4hours.
|
The investigators will evaluate the magnetoencephalography-defined brain connectivity
|
Data will be collected during patient's sleep, which will last 4hours.
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Neurologic Manifestations
- Sleep Wake Disorders
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Propofol
- Dexmedetomidine
Other Study ID Numbers
- 10-03906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Disorders
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
SleepUp Tecnologia em Saúde LtdaActive, not recruiting
-
Landstuhl Regional Medical CenterTerminatedSleep Disorders, Intrinsic | Sleep | Sleep Disturbance | Sleep Deprivation | Sleep Disorders | Sleep Disorders, Circadian RhythmGermany
-
University of California, San DiegoRecruitingSleep Apnea, Obstructive | Sleep Disorder | Sleep | Obstructive Sleep Apnea | Sleep ApneaUnited States
-
Istanbul Sureyyapasa Chest Diseases and Chest Surgery...CompletedSleep Disorder | Obstructive Sleep Apnea of Adult | Patient ComplianceTurkey
-
University of BergenCompletedSleep | Circadian Rhythm Sleep Disorder, Delayed Sleep PhaseNorway
-
Kaiser PermanenteActive, not recruitingInsomnia | Obstructive Sleep Apnea (OSA) | Restless Leg Syndrome (RLS) | Hypersomnia Type; Sleep Disorder | Shift Work Sleep DisordersUnited States
-
Shiphrah Biomedical Inc.Mitacs; University of TorontoRecruitingSleep Disorder | Sleep | Sleep Disturbance | Pregnancy Related | Sleep-Disordered BreathingCanada
-
Matrouh UniversitySuez Canal University; Beni-Suef University; University of Bisha, Saudia ArabiaCompletedSleep Disorder | Sleep Hygiene | Sleep Disorder; Insomnia Type | Sleep Disorder in Elderly | Sleep Disorder, Mental Health | Sleep Disorders, Physical HealthEgypt
Clinical Trials on Normal saline infusion
-
University of CalgaryNot yet recruitingPostural Orthostatic Tachycardia Syndrome | Post Acute Sequelae of SARS CoV 2 Infection
-
University of WashingtonNational Heart, Lung, and Blood Institute (NHLBI); Medic One FoundationCompletedOut-of-hospital Cardiac ArrestUnited States
-
Beth Israel Deaconess Medical CenterAmerican Heart AssociationTerminatedAnemia | Acute Coronary SyndromeUnited States
-
Reproductive Medicine Associates of New JerseyRecruitingInfertility of Uterine OriginUnited States
-
Sunnybrook Health Sciences CentreCompleted
-
Taipei Veterans General Hospital, TaiwanUnknown
-
Queen's UniversityWithdrawnRenal Failure | Contrast Nephropathy
-
McGill University Health Centre/Research Institute...UnknownLiver Failure | Hepatic InsufficiencyCanada
-
Medical University of South CarolinaTerminated